{"text": "bmy announced us approval of liso cel in r r lbcl after gt 2l of systemic therapy the press release states that the target turnaround time is 24 days from its manufacturing facility in bothell wa usa we will be conducting a full thoughts on label review in the coming days"}
{"text": "u s food and drug administration approves bristol myers squibbs breyanzi a new car t cell therapy for adults with bmy"}
{"text": "litigation value should be 4 in my dreamland it is clear bmy screwed the pooch"}
{"text": "fda approves less toxic liso cel in r r large b cell lymphoma bmy breyanzi via"}
{"text": "baml bmy modeling gt 2b peak sales vs 1b consensus and 135m in 2021 25m ahead of expectations"}
{"text": "fda approves bmy s liso cel for r r large b cell lymphoma it s the 4th cd19 car t to us market amp 1st approval of a juno therapy had it come by ye20 it would have been the 2nd of 3 milestones needed to satisfy requirements of 6 8b cvr issued in bmss 74b celgene takeout"}
